CLBT Stock Forecast & Price Target

Cellebrite DI is positioned for a constructive turnaround because new CEO Shiven Ramji is sharpening execution, improving forecasting, and expanding the company’s intelligence-led investigations platform into underpenetrated public-safety workflows. Demand appears strong in defense and intelligence, where ARR grew 25% Y/Y in Q2, while Genesis is gaining traction with more than half a dozen customers and nearly $1M of ARR, suggesting new products can offset slower Inseyets migrations. Even after the Q2 miss, the business still delivered 85.5% gross margin, $31.8 million of adjusted EBITDA, and remains attractive at about 10.5x EV/CY27 FCF on reset numbers.

Cellebrite DI is viewed negatively because roughly 90% of revenue comes from public-sector customers, including a high-teens percentage from U.S. federal, leaving results exposed to budget delays, shutdowns, and elongated procurement cycles. That concentration already showed up in Q2, where ARR of $507.8 million missed consensus and management cut CY26 ARR growth guidance to about 15.5% from roughly 18.5% at the mid-point, while Q2 free cash flow was only $6.0 million versus consensus of $29.7 million. Beyond execution issues, the company faces persistent competitive and technological risk as it must keep pace with new hardware and OS changes, while smartphone makers could patch vulnerabilities that weaken its core device-unlock and data-extraction value proposition.